|
|
Post by oracle on Jan 29, 2015 23:54:48 GMT -5
|
|
|
|
Post by blueice on Jan 30, 2015 0:02:54 GMT -5
Any connection to "the process" ('Alfie, we are not ready to disclose that...')?
|
|
|
|
Post by kc on Jan 30, 2015 0:16:18 GMT -5
I looked at the type of insulin they produce and that is common to the pen. That's not to say that eventually you might be able to produce cartridges for afrezza, but they would have to have the process installed. At this point I do not believe its for our product.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 30, 2015 0:20:52 GMT -5
I looked at the type of insulin they produce and that is common to the pen. That's not to say that eventually you might be able to produce cartridges for afrezza, but they would have to have the process installed. At this point I do not believe its for our product. Iyer said, for the first time, the company will manufacture insulin in cartridges; a newer technology that enhances the production expertise of the company. “This facility will have the capability to ramp up manufacturing volumes to 60 million Insuman cartridges per year, within two to three years of commercial production what is Insuman catridge? |
|
|
|
Post by kc on Jan 30, 2015 0:35:13 GMT -5
MEDICINES
Our principal medicinal products in the field of diabetes are:
Lantus® (insulin glargine), a long-acting human insulin analog, market leader for branded insulins (IMS source). Lantus® is available is more than 120 countries worldwide (2).
Apidra® (insulin glulisine) a rapid-acting human insulin analog (2).
Insuman®, a range of rapid- and intermediate-acting human insulins (2).
Lyxumia® (lixisenatide) is a once-daily prandial GLP-1 receptor agonist (2).
Amaryl®/Amarel® (glimepiride), a sulfonylurea-class hypoglycemic (2).
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 30, 2015 0:48:27 GMT -5
MEDICINES Our principal medicinal products in the field of diabetes are: Lantus® (insulin glargine), a long-acting human insulin analog, market leader for branded insulins (IMS source). Lantus® is available is more than 120 countries worldwide (2). Apidra® (insulin glulisine) a rapid-acting human insulin analog (2). Insuman®, a range of rapid- and intermediate-acting human insulins (2). Lyxumia® (lixisenatide) is a once-daily prandial GLP-1 receptor agonist (2). Amaryl®/Amarel® (glimepiride), a sulfonylurea-class hypoglycemic (2). Insuman comes in pens/vial , why refer to catridges...confusing...i wonder if the reporters are sensible enough or even knoe |
|
|
|
Post by EveningOfTheDay on Jan 30, 2015 1:36:45 GMT -5
I looked at the type of insulin they produce and that is common to the pen. That's not to say that eventually you might be able to produce cartridges for afrezza, but they would have to have the process installed. At this point I do not believe its for our product. Iyer said, for the first time, the company will manufacture insulin in cartridges; a newer technology that enhances the production expertise of the company. “This facility will have the capability to ramp up manufacturing volumes to 60 million Insuman cartridges per year, within two to three years of commercial production what is Insuman catridge? We'll have to wait and see, but considering that the date fits into what could be a reasonable schedule for the expansion of Afrezza's production, I tend to agree that this so called Insuman cartridges are, perhaps, Afrezza cartridges and that the writer is mixing apples and oranges. I will try to figure out exactly how Insuman is manufactured, but if it is pens and vials, a cartridge does not seem to make a lot of sense. Having said this, I would agree with KC that until we do not get a little more clarity on the issue we should not be uncorking the Dom Perignon or booking any tickets to Vegas. |
|
|
|
Post by dreamboatcruise on Jan 30, 2015 2:31:48 GMT -5
MEDICINES Our principal medicinal products in the field of diabetes are: Lantus® (insulin glargine), a long-acting human insulin analog, market leader for branded insulins (IMS source). Lantus® is available is more than 120 countries worldwide (2). Apidra® (insulin glulisine) a rapid-acting human insulin analog (2). Insuman®, a range of rapid- and intermediate-acting human insulins (2). Lyxumia® (lixisenatide) is a once-daily prandial GLP-1 receptor agonist (2). Amaryl®/Amarel® (glimepiride), a sulfonylurea-class hypoglycemic (2). Insuman comes in pens/vial , why refer to catridges...confusing...i wonder if the reporters are sensible enough or even knoe Some pens have replaceable cartridges of insulin. If you look up Novolog in pharmacy system you'll see you can buy a complete pen or just the insulin cartridges. |
|
|
|
Post by EveningOfTheDay on Jan 30, 2015 2:38:43 GMT -5
On a second look, it would seem KC is right. I found the following, www.business-standard.com/article/companies/sanofi-subsidiary-to-set-up-rs-460-cr-insulin-manufacturin-facility-in-telangana-115012901055_1.htmlThis is an excerpt, The facility will manufacture Insuman, a human insulin product from the portfolio of Sanofi’s diabetes treatments. This will be the French global pharma major’s second Insuman manufacturing plant in the world. Chief minister K Chandrasekhar Rao today laid the foundation stone for the plant. The project is coming up in his home constituency of Gajwel in the neighbouring Medak district.
KI Varaprasada Reddy, founder and chairman of Shantha, said this would be a new technology facility where insulin would be manufactured in cartridges. According to him, it has a capacity to ramp up manufacturing volumes to 60 million cartridges a year in 2-3 years of commercial manufacturing. The cartridges manufactured in this plant will be priced at Rs 11 per day. Sanofi India launched Insuman cartridges in 2011.
So it really looks, as DBC is pointing out that this is for pen cartridges. |
|
|
|
Post by _neil on Jan 30, 2015 12:32:35 GMT -5
Ah.. I thought I could be helpful just this once but it's already a resolved question. I will be visiting that city next month.. maybe get some inside info while I'm there  |
|
